Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistence and booster immunogenicity study of 13-valent pneumococcal conjugate vaccine in previously immunized healthy children
2009-015321-37Phase 3Completed
- Sponsor
- Wyeth
- Start
- Dec 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease, sponsored by Wyeth. Primary endpoint: Serotype-specific IgG concentration 1 month after a single dose of 13vPnC. Started Dec 2009; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2009-015321-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015321-37.